BRCA1 and cancer: However, patients with BRCAmut cancers showed a significant improved overall survival compared to those with nonBRCA cancers (Hazard Ratio (HR) = 0.52, P = 0.025; Fig. 5B), whereas, again, BRCA1 promoter methylation showed no significant survival advantage.